Supriya Lifescience Limited headquartered in Mumbai, India is a public listed generic pharmaceutical company established in 1987 dedicated to developing, commercializing APIs & FDFs to treat patients with various diseases and infections. The API facility located at Lote, Maharashtra, India is multiple times USFDA, EDQM/EUGMP approved, and Health Canada approved whereas the Formulation facility located at Ambernath, Mumbai, India is EUGMP compliant.
Supriya Lifescience Ltd. has a well-established presence in API Manufacturing with focus in products of various therapeutic segments like – Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, Anti- Asthmatics etc.
We take pride in setting the products, processes and the systems as per the industry standards and in making continuous improvement to deliver quality products. Our facility is spread across an area of 47,000 sq.m. with delineated areas for warehouse, QA, QC, R & D, production and finished products (dedicated blocks for different therapeutic segments). The plant has current capacity of 550 KL and supported with multiple clean rooms for finished products. As a part of our capacity expansion plan, our capacity would be approximately 1000+ KL by 2024.
Backed by strong R&D, 14 active USDMFs, 8 active CEPs & World wide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. Our focus is to develop APIs and Intermediates for both Innovators, Generic companies and we also partner exclusively as CMO.
Supriya Lifescience Ltd. has a global footprint that extends across 86 countries. Our diverse repertoire of Active Pharmaceutical Ingredients includes over 38 products that enjoy the implicit trust of a loyal global clientele.
We meet the most demanding quality standards and are registered in over 35 countries.